Candel Therapeutics Inc. (CADL)
| Bid | 7.9 |
| Market Cap | 351.58M |
| Revenue (ttm) | 2.47M |
| Net Income (ttm) | -72.52M |
| EPS (ttm) | -1.73 |
| PE Ratio (ttm) | -4.57 |
| Forward PE | -7.36 |
| Analyst | Buy |
| Ask | 8.1 |
| Volume | 1,084,769 |
| Avg. Volume (20D) | 4,333,498 |
| Open | 9.13 |
| Previous Close | 8.97 |
| Day's Range | 7.67 - 9.09 |
| 52-Week Range | 1.34 - 14.60 |
| Beta | -1.25 |
About CADL
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of hi...
Analyst Forecast
According to 4 analyst ratings, the average rating for CADL stock is "Buy." The 12-month stock price forecast is $22, which is an increase of 178.30% from the latest price.
3 days ago · proactiveinvestors.com
Candel Therapeutics CEO discusses promising Phase 2 pancreatic cancer trial results - ICYMICandel Therapeutics Inc (NASDAQ:CADL) CEO Dr Paul Peter Tak talked with Proactive about the encouraging results from the phase 2 trial of its investigational medicine CAN-2409 for borderline resectabl...
6 days ago · proactiveinvestors.com
Candel Therapeutics reports significant survival benefit for pancreatic cancer therapyCandel Therapeutics Inc (NASDAQ:CADL) announced positive final overall survival data from its Phase 2 clinical trial of CAN-2409, an investigational immunotherapy for pancreatic ductal adenocarcinoma ...
1 month ago · proactiveinvestors.com
Candel Therapeutics advancing lead candidate targeting prostate cancer towards FDA submissionCandel Therapeutics Inc (NASDAQ:CADL) has provided a corporate update, highlighting anticipated milestones for this year building upon significant achievements in 2024. Updated overall survival data...
1 month ago · seekingalpha.com
Best-Performing Stocks Of 2024Best-Performing Stocks Of 2024
2 months ago · proactiveinvestors.com
2025 biotech outlook: Small-cap innovators tackling chronic and rare diseasesIn the New Year, many small-cap biotech companies will be advancing promising clinical trials with innovative therapies aimed at addressing significant unmet medical needs. Key trials include those fo...
2 months ago · proactiveinvestors.com
Candel Therapeutics rides high on promising Phase 3 data, funding boostCandel Therapeutics Inc (NASDAQ:CADL) shares skyrocketed by nearly 43% on Thursday following a string of positive news surrounding the company's cancer drug pipeline. Last week the Needham, Massachuse...
2 months ago · proactiveinvestors.com
Candel Therapeutics raises $92M in public offering following prostate cancer trial successCandel Therapeutics Inc (NASDAQ:CADL) announced on Monday the completion of a public offering that raised approximately $92 million in gross proceeds. The offering included 12 million shares of common...
